UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2026

VERADIGM INC.
(Exact name of Registrant as Specified in Its Charter)

Delaware	000-32085	36-4392754
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

222 Merchandise Mart Chicago, Illinois	60654
(Address of Principal Executive Offices)	(Zip Code)

Registrant's Telephone Number, Including Area Code: 800 334-8534

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	MDRX	N/A (OTC Expert Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

As previously announced, the Company will present at the 2026 Jefferies Healthcare Services and Technology Conference in Nashville, Tennessee on September 15, 2026 and will participate in the Deutsche Bank 2026 Healthcare Summit in New York, New York on September 16, 2026. A copy of the Company's presentation is furnished as Exhibit 99.1. The Company intends to use this presentation at other investor conferences.

The information furnished pursuant to this Item shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	
99.1	Copy of Veradigm Inc. presentation slides
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VERADIGM INC.

September 15, 2026

By: /s/ Eric Jacobson
Eric Jacobson
Senior Vice President, Interim General Counsel & Corporate Secretary

Exhibit 99.1

veradigm®

SEPTEMBER 2026

Investor Deck

VDMT-2697-AUG-2026

veradigm.com

Disclaimer and Forward-Looking Statement Information

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the Company’s preliminary estimated unaudited 2025 financial information, the Company's anticipated revenue growth and future financial performance, the Company's business and growth strategies, including its "reset, recover, reignite" strategy, the Company's product portfolio optimization and anticipated product roadmap, and the Company’s anticipated SEC filings and relisting on a national securities exchange. These forward-looking statements are based on the current beliefs and expectations of the Company’s management with respect to future events, only speak as of the date that they are made, and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “continue,” “can,” “may,” “look forward,” “aims,” “hopes,” and “seeks” and similar terms, although not all forward-looking statements contain such words or expressions. Actual results could differ significantly from those set forth in the forward-looking statements.

Important factors that could cause actual results to differ materially from those expressed or implied in these forward-looking statements include, but are not limited to: the preliminary and unaudited nature of the Company’s estimated 2025 financial information, which remains subject to the completion of the Company’s year-end close, review and audit procedures and could change materially; the Company’s ability to complete its delinquent periodic reports and to become and remain current in its SEC reporting obligations; the risk that the Company’s Common Stock is not relisted on a national securities exchange, or, if relisted, does not remain listed or does not develop an active trading market; the Company’s ability to successfully execute its “reset, recover, reignite” strategy, including product portfolio optimization, investment in and scaling of higher-growth solutions and deeper alignment with independent physician practices; the risk that operational, technological and organizational changes, including workforce optimization and a centralized global operating structure, prove more complex, costly or time-consuming than expected or disrupt operations or customer relationships; the Company’s ability to maintain and expand relationships with existing customers; intense competition and rapid technological change in the markets for the Company’s products and services, including with respect to AI and machine learning; risks associated with the Company’s expanding use of AI; cybersecurity incidents, IT system failures and network disruptions affecting protected health information or other sensitive data; and the other factors discussed in Part I, Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal years ended December 31, 2023 and December 31, 2024 filed with the SEC on May 26, 2026, and in the Company’s subsequent filings with the SEC.

The Company does not undertake to update any forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes over time, except as required by law.

Overview

We are a healthcare data and technology company connecting providers, payers and life science companies

$584-589 M Expected Revenue in 2025	**2,300** Associates	**148 M** Patient Records	**1.7 B** Patient Visits	**$60 B** Addressable Market

WE SERVE THREE SEGMENTS CONNECTED BY OUR HEALTH NETWORK ARCHITECTURE

Providers
Leading EHR, practice management and revenue cycle provider for independent physician groups

Payers / Health Plans
Risk adjustment, quality reporting and care-gap closure at scale

Life Sciences
Real-world data, clinical evidence products and point-of-care media

Investment Highlights

We are a Leader in Healthcare Technology

We empower independent physician practices with technology that positions us at the intersection of clinical workflows & data monetization

- Our highly recurring Provider market footprint enables us to leverage capabilities across the Payer Health and Life Sciences markets

Veradigm Health Network Architecture

Provides independent practices a single real-time view of their clinical, financial, and operational performance

- Products across all three segments feed one connected data layer that powers our AI capabilities

Reset, Recover, Reignite

Our strategy is in place to accelerate top-line growth and improve profitability beginning in 2026

- Our transformation efforts aimed at simplification & innovation are helping to fuel our flywheel

Audit and Filings

Our recent filings and what we expect for 2026

- Recently filed our 2023 and 2024 10K. 2025 audit underway
- An expected 10K filing in the later part of 2026
- Expect to relist our shares on a national exchange once we are current with our filings

Growth Initiatives

Maintain a strong balance sheet to support our growth initiatives

- $120 million in cash and cash equivalents at year end 2025
- Debt of $75 million

We are in a strong position to drive sustainable growth andcreate long-term shareholder value

Our Transformation

Where We Have Been

NO REVENUE GROWTH
Flat, +/-0% since 2022, even with M&A and strategic investments

POOR CUSTOMER RETENTION
- Customer dissatisfaction, notably in the Provider EHRs: Estimated gross revenue retention (GRR) of 82%

SILOED, COMPLEX PRODUCT & PLATFORM
Most product partners erode gross margin and add complexity

HOLDING COMPANY WITH SILOED BUSINESS UNIT WORKFORCE
500+ vendor relationships and 2,000+ POs; three Salesforce instances

Where We Are Going

GROWTH TO ACCELERATE BEGINNING IN 2026
- Growth 'bets' within each segment, funded and road mapped
- Unify RevOps, enterprise systems, sales forecast and close process

IMPROVED CUSTOMER RETENTION
- Enterprise-wide NPS uplift plan with OKR to improve NPS by +10
- New strategic account planning, new client management model, and revised incentive framework

ONE CONNECTED PLATFORM
- Bring together development, AI leadership talent, and infrastructure
- Rationalize product & solution portfolio: invest, sustain, sunset/sell while rethinking product partnerships

PEOPLE: 'ENTREPRENEURIAL' OPERATING SYSTEM
- OKRs at the individual level (in Workday) for 100% of team

Veradigm Management Team

WE HAVE THE RIGHT TEAM IN PLACE TO EXECUTE ON OUR STRATEGY

Don Trigg
CHIEF EXECUTIVE OFFICER

Tehsin Syed
CHIEF TECHNOLOGY & PRODUCT OFFICER

Troy Tetzlaff
SVP REVENUE OPERATIONS

Tally Baker
CHIEF HUMAN RESOURCES OFFICER

Eric Jacobson
INTERIM GENERAL COUNSEL

Jonathan Vipperman
SVP AND GM PROVIDER

Jay Bhattacharyya
SVP AND GM PAYER

Christian Greyenbuhl
CHIEF FINANCIAL OFFICER

SELECTED PRIOR EXPERIENCE

Veradigm Board of Directors

OUR BOARD OF DIRECTORS BRINGS A LEVEL OF OVERSIGHT AND EXPERIENCE TO HELP MANAGEMENT EXECUTE ON ITS GROWTH STRATEGIES

Don Trigg
CHIEF EXECUTIVE OFFICER

Vinit Asar[2]
DIRECTOR

Bruce Felt[3]
DIRECTOR

Susan Rodriguez
DIRECTOR

JS

Jonathan Sacks
DIRECTOR

Louis Silverman[1]
DIRECTOR

Dave Stevens[4]
DIRECTOR

Carol Zierhoffer
DIRECTOR

(1) Chairman of the Board
(2) Chairman Nominating and Governance Committee
(3) Chairman Audit Committee
(4) Chairman Compensation Committee

Veradigm Addresses a Large Market Opportunity With Current and Adjacent Products

Total Addressable Market of ~$60B



Column width proportional to each segment's total TAM; each column indexed to 100%.

Note: Incremental SAM and incremental TAM include current and adjacent products | Billions of USD
Source: L.E.K. research and analysis

Reset. Recover. Reignite.

veradigm®

Reignite Growth

WE WIN WHEN WE HAVE:

Strong alignment with independent physician practices	A deep, high ROI provider solution footprint (Revenue Cycle, Practice Ops)
Payer and Life Sciences clients can collaborate effectively with providers	When providers want to collaborate with Payers and Life Sciences, we make it frictionless and easy for them

Driving to reaccelerate long-term profitable growth

We Operate in Three Segments Connected by our Health Network Architecture

	PROVIDERS	PAYERS	LIFE SCIENCES
2025 ESTIMATED REVENUE	$463-467M	$71-72M	~$50M
GROWTH STRATEGIES	Cross-sell RCS offering	Large national payers	Captive data source
	Win new clients	Chart review	Digital advertising platform
	Enhance client experience	Care gap closure	Enable AI drug discovery models

Leverage our Health Network Architecture and AI Capabilities

Provider Solutions Overview

EHRs
- Veradigm Suite (EHR & PM) for mid-size practices
- Practice Fusion for small practices

Revenue Cycle
- Veradigm Revenue Cycle Services
- Veradigm Payerpath

Documentation & Coding
- Veradigm Ambient Scribe
- Veradigm Coding Services

Patient Engagement
- Veradigm FollowMyHealth portal
- Mobile Patient Experience

Prescribing & Connectivity
- Veradigm ePrescribe
- Veradigm DORN – Lab Offering

Care Gap & Quality
- Veradigm Payer Insights
- Veradigm eChart Courier

Enabling Independent practices to remain independent and thrive in a consolidating market

Provider | Representative VEHR Clients

Acute Care Surgical Specialists	Center City Pediatrics	Clinix Center for Health	Dothan Specialty Clinic
family medical center	fafp France Avenue Family Physicians	MAWS Medical Associates of Wall Street	Michigan Vascular Center ...first & foremost
north atlanta pediatrics	Silver Pine Medical Group	The Clinic www.clinicsofnorthtexas.com	Women First of Louisville, PLLC Obstetrics & Gynecology

We have a leading position with small- to medium-size independent physician practices

Payer Solutions | Leveraging Provider Data at Scale

Analytics

- Risk Adjustment
- Quality / HEDIS
- Health Equity
- Utilization

Clinical Data Exchange

- Chart retrieval
- Point of care alerts

Services

- Care gap services
- Member engagement
- Coding review

Submissions

- Encounter submissions

Maximize financial performance and clinical outcomes for health plans and MCOs

Life Sciences | Leveraging Provider Data at Scale [1]

Data & Real-World Evidence	Clinical Intelligence	Commercial Intelligence	Regulatory & Safety Solutions
Data licensing	**Rules-based NLP**	Commercial analytics	**Pregnancy reporting**
Clinical Evidence Workbench	Generative AI	**Patient journey analytics**	Pharmacovigilance
Health economics and outcomes research & real-world evidence	Chart abstraction	Brand insights & market access	**Regulatory reporting**
Medical Affairs	**Patient identification**	Omnichannel measurement	Post market safety surveillance
Women's Health Insight	**Clinical summarization**	**Digital health media**	Compliance subscriptions
	Evidence automation		

Serving pharmaceutical and biotech companies with real-world data, evidence generation, and point of care advertising

(1) Bold indicates current offerings

Veradigm AI Product Strategy

Before the visit

- Agentic intake and insurance check
- Predictive no show risk
- Schedule optimization

During the visit

- Ambient clinical documentation
- Agentic payer formulary check
- Agentic prior authorization

After the visit

- Agentic documentation and coding
- Agentic referral management
- Agentic chronic disease management

Agents and AI embedded seamlessly to increase our clients' efficiency

Veradigm Health Network Architecture

Products across all three segments feed one connected data layer that powers our AI capabilities



Health Network Architecture and Agents Working Together

THE SYSTEM OF WORK

Health Network Architecture

The connection layer.
One unified data layer across your Veradigm products.

+

Agentic AI

The action layer.
Review charts, draft documentation, build claims, surface risks, take action.

SYSTEMS OF RECORD EHR | Practice Management | Payerpath | Revenue Cycle Management | FollowMyHealth

Veradigm Investment Summary

Reset, Recover, + Reignite

We are executing on our Reset, Recover and Reignite plan.

Independent Physicians

We will continue to focus on our core markets including serving independent physician groups

- We'll do this while augmenting growth in the payer and life science segments.

Veradigm Health Network

This architecture is central to our growth strategy.

- Provides independent practices a single real-time view of their clinical, financial, and operational performance
- Helps close a capability gap that has historically separated independent practices from large health systems.

Artificial Intelligence

Our provider clients are looking to us to bring AI capabilities to their practices

- To create workflow efficiencies in their practices as they desire to stay independent.

Financial Discipline

Maintain this while making the appropriate investments

- To leverage our capabilities to support our long-term sustainable growth model.

The company is in a strong position to create shareholder value

veradigm®

TRANSFORMING HEALTH, *Insightfully*

veradigm.com